PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$71.70 USD
-0.61 (-0.84%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $71.70 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.70 USD
-0.61 (-0.84%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $71.70 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum F VGM
Zacks News
PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer
by Zacks Equity Research
PROCEPT BioRobotics receives FDA's approval to begin a pivotal randomized clinical study to assess the use of Aquablation therapy in treating prostate cancer patients.
PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance
by Zacks Equity Research
PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment.
PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS
by Zacks Equity Research
PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 3.85% and 6.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYX
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 7.27% and 6.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -43.55% and 20.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Soars 3.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 3.68% and 0.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integra LifeSciences (IART) Q4 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics
by Zacks Equity Research
Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
Strength Seen in PROCEPT BioRobotics Corporation (PRCT): Can Its 15.1% Jump Turn into More Strength?
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Predict a 25.54% Upside in PROCEPT BioRobotics Corporation (PRCT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for PROCEPT BioRobotics Corporation (PRCT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Edwards Lifesciences (EW) Q3 Earnings Match Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 0.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care, Inc. (TNDM) Soars 6.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of 1.75% and 9.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -6.78% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.